NCT02071862 - Study of the Glutaminase Inhibitor CB-839 in Solid Tumors | Biotech Hunter

Enrollment

210

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

March 31, 2019

Study Completion Date

March 31, 2019

Conditions

Solid TumorsTriple-Negative Breast CancerNon Small Cell Lung CancerRenal Cell CarcinomaMesotheliomaFumarate Hydratase (FH)-Deficient TumorsSuccinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST)Succinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal Stromal TumorsTumors Harboring Isocitrate Dehydrogenase-1 (IDH1) and IDH2 MutationsTumors Harboring Amplifications in the cMyc Gene

Interventions

DRUG

CB-839

CB-839 monotherapy

DRUG

Pac-CB

CB-839 in combination with standard dose paclitaxel

DRUG

CBE

CB-839 in combination with standard dose everolimus

DRUG

CB-Erl

CB-839 in combination with standard dose erlotnib

DRUG

CBD

CB-839 in combination with standard dose docetaxel

DRUG

CB-Cabo

CB-839 in combination with standard dose cabozantinib

Trial Locations (13)

10032

Columbia University Medical Center, New York

10065

Memorial Sloan Kettering Cancer Center, New York

19104

University of Pennsylvania, Abramson Cancer Center, Philadelphia

20892

NIH - NCI - Center for Cancer Research, Bethesda

30322

Winship Cancer Institute of Emory School of Medicine, Atlanta

34232

Florida Cancer Specialists, Sarasota

37203

Tennessee Oncology, PLLC, Nashville

77030

University of Texas MD Anderson Cancer Center, Houston

94143

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco

94305

Stanford University Medical Center, Stanford

02114

Massachusetts General Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston